急性脑梗死的超适应证静脉溶栓治疗的安全性及有效性

Safety and Efficacy of Off-label Intravenous Thrombolysis in Acute Ischemic Stroke

静脉溶栓治疗是急性脑梗死最有效的治疗方法,可显著改善患者的临床预后。由于存在多种溶栓治疗禁忌证,仅少部分急性脑梗死患者可接受静脉溶栓治疗。而这些溶栓禁忌证并非源于有效证据。大量证据表明部分溶栓禁忌证可从静脉溶栓治疗中获益。超适应证溶栓治疗并非伴随不良预后的风险增加。本研究主要分析急性脑梗死超适应证静脉溶栓治疗的安全性及有效性。

Intravenous thrombolysis is the most effective therapy to improve clinical outcomes in patients with acute ischemic stroke(AIS).However,due to numerous contraindications,many of which are not based on evidence,only a small fraction of patients with AIS receive intravenous thrombolysis.There is mounting evidence suggesting that patients with AIS may still benefit from intravenous thrombolysis despite the presence of some contraindications.Off-label thrombolysis dose not confer a higher risk for adverse outcome.The aim of this paper is to analyze the safety and the efficacy of off-label thrombolysis in AIS patients.